Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Haretos

Geriatric Medicine Pittsburgh, PA Medical Doctor

NPI 1114087160 CMS profile 277684

875 Greentree Rd Ste 325, Bethany Hospice, Pittsburgh, PA 15220

Open in the dashboard

General payments

$8,678

399 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Haretos of Pittsburgh, PA is reported in the CMS Open Payments database as having received $8,678 across 399 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,174 48
2024 General $858 40
2023 General $784 39
2022 General $1,016 54
2021 General $940 53
2020 General $1,258 64
2019 General $2,648 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Haretos
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to John Haretos were reported at $1,174. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year John Haretos Geriatric Medicine median Middle half National median
2019 $2,648 $122 $40–$435 $163
2020 $1,258 $98 $25–$349 $114
2021 $940 $125 $34–$441 $132
2022 $1,016 $124 $36–$408 $149
2023 $784 $121 $41–$383 $160
2024 $858 $134 $41–$435 $164
2025 $1,174 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,494 84 payments
  2. Janssen Pharmaceuticals, Inc $1,449 33 payments
  3. Lilly USA, LLC $1,301 80 payments
  4. AbbVie, Inc. $973 46 payments
  5. Pfizer Inc. $952 43 payments
  6. Astellas Pharma US Inc $458 18 payments
  7. Kowa Pharmaceuticals America, Inc. $237 16 payments
  8. Allergan Inc. $226 15 payments
  9. Abbott Laboratories $186 10 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $139 3 payments
  11. Other $1,264 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,673 398 payments
  2. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. ELIQUIS $885 39 payments
  2. Ozempic $874 53 payments
  3. NURTEC ODT $736 33 payments
  4. XARELTO $666 23 payments
  5. MOUNJARO $610 39 payments
  6. UBRELVY $568 29 payments
  7. QULIPTA $560 24 payments
  8. INVOKANA $558 12 payments
  9. RYBELSUS $537 32 payments
  10. PAXLOVID $482 21 payments
  11. Other $4,248 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 103 drugs

Part D claims

3,643

Median for Internal Medicine: 777

Drug cost

$475,323

Median for Internal Medicine: $73,373

Branded share of claims

19.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tasimelteon Generic 12 $244,280
Mounjaro Tirzepatide Brand 40 $51,325
Eliquis Apixaban Brand 28 $37,837
Jardiance Empagliflozin Brand 34 $36,208
Ozempic Semaglutide Brand 21 $31,851
Xarelto Rivaroxaban Brand 14 $8,160
Sucralfate Generic 11 $4,936
Synthroid Levothyroxine Sodium Brand 48 $3,717
Atorvastatin Calcium Generic 218 $3,418
Edarbi Azilsartan Medoxomil Brand 11 $3,047

The 10 drugs with the highest cost, of 103 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$34,526

Of which drugs: $2,788

Medicare patients

107

Average age 75

Services billed

643

58 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 45%
Diabetes 24%
Ischemic heart disease 22%
Depression 17%
Osteoporosis 13%
Heart failure 12%
Atrial fibrillation 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 28 29 $2,353
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 18 27 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $169
$169 — —
MOUNJARO
  • Lilly USA, LLC $128
$128 40 —
ELIQUIS
  • PFIZER INC. $94
  • E.R. Squibb & Sons, L.L.C. $21
$116 28 —
UBRELVY
  • AbbVie, Inc. $99
$99 — —
NURTEC ODT
  • PFIZER INC. $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

399 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record